GlassScriptPhysician profile
Waqas Jehangir
NPI 1659752541
$22,876.17
in general payments reported to CMS, 2019-2025
29 companies · $3,402 in 2025
The $3,402 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $64.99 · 2021: $1,565 · 2022: $8,171 · 2023: $3,743 · 2024: $5,735 · 2025: $3,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $312 · Education: $74.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,494.00 |
| Food and Beverage | $312.25 |
| Education | $74.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $5,798.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,830.42 | 2022-2023 | Abecma |
| Beigene USA, INC. | $2,950.00 | 2024 | Brukinsa |
| Janssen Scientific Affairs, LLC | $2,905.73 | 2023-2025 | Darzalex, Carvykti, Talvey |
| Daiichi Sankyo INC. | $2,060.00 | 2023-2025 | Vanflyta |
| Morphosys, US INC. | $1,440.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,050.00 | 2023-2024 | Calquence |
| Glaxosmithkline, LLC. | $654.53 | 2025 | Ojjaara |
| Cardinal Health 110 LLC | $400.00 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $400.00 | 2024 | |
| Pfizer INC. | $325.00 | 2024-2025 | |
| Sobi, INC | $200.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Amgen INC. | $164.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $142.18 | 2021-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $106.12 | 2025 | Rytelo |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Legend Biotech USA INC. | $57.01 | 2025 | Carvykti |
| Celgene Corporation | $44.10 | 2025 | Reblozyl |
| Mallinckrodt Hospital Products INC. | $25.41 | 2024 | Cellex |
| Rigel Pharmaceuticals, INC. | $18.61 | 2024 | Rezlidhia, Tavalisse |
| Genentech USA, INC. | $17.75 | 2024 | Venclexta |
| Biolinerx USA, INC. | $15.81 | 2024 | Aphexda |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waqas Jehangir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.